Colossal Biosciences, founded in 2021 and headquartered in Dallas, Texas, has raised over $568 million through multiple funding rounds to support its genetic engineering and de-extinction work. Major financings include a $60 million Series A led by Thomas Tull and early strategic investors, a $162.6 million Series B backed by USIT and partners, and a $320 million Series C in September 2025 led by TWG Global with Mark Walter and Thomas Tull. This last round valued the company at about $10.2–11 billion as it pursues advanced synthetic biology, de-extinction projects, and commercial spin-outs that apply its core technologies.